ArticleOncogene2010
Human stem cells expressing novel TSP-1 variant have anti-angiogenic effect on brain tumors.
Article in Oncogene, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 71 citations in OpenAlex.
- NKG2D-CAR-targeted iPSC-derived MSCs efficiently target solid tumors expressing NKG2D ligand.iScience · 2025Article
- The Contributions of Thrombospondin-1 to Epilepsy Formation.Neuroscience bulletin · 2024Review
- Tumor-tropic Trojan horses: Using mesenchymal stem cells as cellular nanotheranostics.Theranostics · 2024Review
- Mesenchymal stem/stromal cells in cancer therapy.Journal of hematology & oncology · 2021Review
- Cytotoxic Engineered Induced Neural Stem Cells as an Intravenous Therapy for Primary Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer.Molecular cancer therapeutics · 2021Article
- Triple-negative breast cancer: new treatment strategies in the era of precision medicine.Science China. Life sciences · 2021Review
- Neural Stem Cell-Based Therapies and Glioblastoma Management: Current Evidence and Clinical Challenges.International journal of molecular sciences · 2021Review
- Engineered stem cells targeting multiple cell surface receptors in tumors.Stem cells (Dayton, Ohio) · 2020Review
- Nanoparticles for Stem Cell Therapy Bioengineering in Glioma.Frontiers in bioengineering and biotechnology · 2020Review
- Exercise improves aging-related decreased angiogenesis through modulating VEGF-A, TSP-1 and p-NF-Ƙb protein levels in myocardiocytes.Journal of cardiovascular and thoracic research · 2020Article
- Nanocarriers and nonviral methods for delivering antiangiogenic factors for glioblastoma therapy: the story so far.International journal of nanomedicine · 2019Review
- Mesenchymal stem cell therapy assisted by nanotechnology: a possible combinational treatment for brain tumor and central nerve regeneration.International journal of nanomedicine · 2019Review
- Recent advances in stem cells therapy: A focus on cancer, Parkinson's and Alzheimer's.Journal, genetic engineering & biotechnology · 2018Review
- Concise Review: Neural Stem Cell-Mediated Targeted Cancer Therapies.Stem cells translational medicine · 2018Review
- Intranasal delivery of stem cell-based therapies for the treatment of brain malignancies.Expert opinion on drug delivery · 2018Review
- Gene Delivery Approaches for Mesenchymal Stem Cell Therapy: Strategies to Increase Efficiency and Specificity.Stem cell reviews and reports · 2017Review
- Review
- Stem cell-based therapies for tumors in the brain: are we there yet?Neuro-oncology · 2016Review
- Engineering Stem Cells for Biomedical Applications.Advanced healthcare materials · 2016Review
- Stem cell-based therapies for cancer treatment: separating hope from hype.Nature reviews. Cancer · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
Novel therapeutic agents combined with innovative modes of delivery and non-invasive imaging of drug delivery, pharmacokinetics and efficacy are crucial in developing effective clinical anticancer therapies. In this study, we have created and characterized multiple novel variants of anti-angiogenic protein thrombospondin (aaTSP-1) that comprises unique regions of three type-I-repeats of TSP-1 and used engineered human neural stem cells (hNSC) to provide sustained on-site delivery of secretable aaTSP-1 to tumor-vasculature. We show that hNSC-aaTSP-1 has anti-angiogenic effect on human brain and dermal microvascular endothelial cells co-cultured with established glioma cells and CD133+ glioma-initiating cells. Using human glioma cells and hNSC engineered with different combinations of fluorescent and bioluminescent marker proteins and employing multi-modality imaging techniques, we show that aaTSP-1 targets the vascular-component of gliomas and a single administration of hNSC-aaTSP-1 markedly reduces tumor vessel-density that results in inhibition of tumor-progression and increased survival in mice bearing highly malignant human gliomas. We also show that therapeutic hNSC do not proliferate and remain in an un-differentiated state in the brains of glioma-bearing mice. This study provides a platform for accelerated development of future cell-based therapies for cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.